疣贅(Warts):治療薬パイプラインレビュー

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC10624IDB)
◆英語タイトル:Warts - Pipeline Review, H2 2018
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC10624IDB
◆発行日:2018年7月17日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site PriceUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise PriceUSD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[疣贅(Warts):治療薬パイプラインレビュー]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Warts – Pipeline Review, H2 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Warts – Pipeline Review, H2 2018, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Warts – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 17, 2, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Warts – Overview
Warts – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Warts – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Warts – Companies Involved in Therapeutics Development
Aclaris Therapeutics Inc
Agilvax Inc
BioMAS Ltd
Cadila Healthcare Ltd
Cutanea Life Sciences Inc
Cytovation AS
G&E Corp
Genetic Immunity Inc
Laboratories Ojer Pharma SL
LEO Pharma A/S
Maruho Co Ltd
Nielsen Biosciences Inc
Novan Inc
Novartis AG
Pfizer Inc
Promius Pharma LLC
RXi Pharmaceuticals Corp
Tamir Biotechnology Inc
Vaxart Inc
Verrica Pharmaceuticals Inc
Warts – Drug Profiles
(digoxin + furosemide) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
854-A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Albicin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AX-03 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Condyloma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyPep-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DFD-05 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FIT-039 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
furosemide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus [serotypes 6, 11] (bivalent) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human papillomavirus vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HupaDerm – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrogen peroxide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imiquimod SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ingenol mebutate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LFX-453 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omiganan pentahydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pefcalcitol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
povidone iodine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-210 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranpirnase – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RKP-00156 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Samcyprone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-206 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teslexivir – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-103 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Warts – Dormant Projects
Warts – Discontinued Products
Warts – Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir for the Treatment of Condyloma
May 18, 2018: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone for the Treatment of Common Warts
Apr 04, 2018: RXi Pharmaceuticals to Present on Samcyprone at the International Investigative Dermatology Conference
Mar 19, 2018: Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts
Jan 08, 2018: Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts
Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
Sep 06, 2017: RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
Jun 29, 2017: Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts
Apr 26, 2017: Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution
Mar 02, 2017: Novan’s Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting
Mar 01, 2017: Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference
Nov 29, 2016: Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206
Aug 18, 2016: Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
Jul 30, 2016: Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts
Jul 21, 2016: RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Warts, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Warts - Pipeline by Aclaris Therapeutics Inc, H2 2018
Warts - Pipeline by Agilvax Inc, H2 2018
Warts - Pipeline by BioMAS Ltd, H2 2018
Warts - Pipeline by Cadila Healthcare Ltd, H2 2018
Warts - Pipeline by Cutanea Life Sciences Inc, H2 2018
Warts - Pipeline by Cytovation AS, H2 2018
Warts - Pipeline by G&E Corp, H2 2018
Warts - Pipeline by Genetic Immunity Inc, H2 2018
Warts - Pipeline by Laboratories Ojer Pharma SL, H2 2018
Warts - Pipeline by LEO Pharma A/S, H2 2018
Warts - Pipeline by Maruho Co Ltd, H2 2018
Warts - Pipeline by Nielsen Biosciences Inc, H2 2018
Warts - Pipeline by Novan Inc, H2 2018
Warts - Pipeline by Novartis AG, H2 2018
Warts - Pipeline by Pfizer Inc, H2 2018
Warts - Pipeline by Promius Pharma LLC, H2 2018
Warts - Pipeline by RXi Pharmaceuticals Corp, H2 2018
Warts - Pipeline by Tamir Biotechnology Inc, H2 2018
Warts - Pipeline by Vaxart Inc, H2 2018
Warts - Pipeline by Verrica Pharmaceuticals Inc, H2 2018
Warts - Dormant Projects, H2 2018
Warts - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Warts, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC10624IDB )"疣贅(Warts):治療薬パイプラインレビュー" (英文:Warts - Pipeline Review, H2 2018)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。